New Clinical Data Highlights Onera Health’s Patch-Based Home Polysomnography Solution at SLEEP 2025

4.6.2025 14:00:00 CEST | Business Wire | Press Release

Onera Health, a leader in transforming remote sleep diagnostics and monitoring, has today announced that its patient-applied patch-based home Polysomnography Solution will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2025 conference. The MedTech company will showcase this innovative solution at booth #1145 during the largest annual conference, which brings together leading experts and innovators in the field of sleep medicine. Furthermore, Onera Health will host a symposium on "Advancing Access to PSG" on Monday, June 9.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604390799/en/

A female patient is sleeping while undergoing a sleep study with Onera Health's home Polysomnography solution.

The 39th annual meeting of the Associated Professional Sleep Societies (APSS) will present the latest clinical data and insights that promise to reshape the landscape of sleep medicine. This year's conference will take place from June 8 to 11, 2025, in Seattle, Washington.

“We are excited to see our Patch-based Type II Polysomnography System highlighted in four different presentations and to be an integral part of the evolving field of sleep medicine by advancing access to the gold standard of PSG sleep testing,” states Ruben de Francisco, Founder and CEO of Onera Health.

The clinical utility of the Onera home PSG system will be presented in four poster presentations. Details of the presentations are as follows:

Title: Assessment of Disease Burden in PAP-Intolerant OSA Patients Using Home Polysomnography: A Pilot Study
Authors: Heiser C et al.
Poster Board Number: #219
Poster Presentation Date and Time: June 9, 2025, 10:00 - 11:45 am
Abstract ID: 661

Title: Signal Quality and Recording Characteristics of Patient-Applied Home Polysomnography: A Real-World Analysis Across US and European Settings
Authors: Dimitrov T et al.
Poster Board Number: #543
Poster Presentation Date and Time: June 10, 2025, 11:00 - 11:45 am
Abstract ID: 1666

Title: Validation of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #319
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 677

Title: Patient Perception of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #320
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 678

Additional presentations by experts from leading institutions will feature validation results, insights from real-world implementation, and the clinical implications of home PSG testing during a symposium titled "Expanding Access, Enhancing Outcomes: The Future of Sleep Diagnostics with Home Polysomnography," which will be hosted by Onera Health on June 9.

“Home polysomnography addresses significant challenges, including the shortage of in-laboratory beds, technicians, and sleep physicians. This shortage has led to escalating costs and an increasing unmet clinical demand, with many patients suffering from sleep disorders remaining undiagnosed. This symposium aims to provide valuable insights into how hPSG can enhance patient care pathways and is already beginning to reshape the landscape of sleep healthcare by broadening access to gold standard PSG testing. I am confident that it will foster engaging discussions with esteemed panelists regarding the emerging opportunities for remote sleep diagnostics and care,” explains Ruben de Francisco.

Attendees can anticipate the following presentations:

David P. White, MD, part-time Professor of Medicine at Harvard Medical School – "The Perfect Storm: Why Sleep Medicine Needs to Transform Now"
Thomas Penzel, PhD, Charité University Hospital Berlin – "Home Polysomnography Comes of Age: Validation Study Results"
Anupamjeet Kaur Sekhon, MD, Kaiser Permanente Fontana Medical Center– "From Lab to Home: Implementing Home Sleep Testing at Scale"

About Onera Health

Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the United States. For further information, please visit onerahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250604390799/en/

Contacts

Swea Ann Hagenhoff
E: media@onerahealth.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom